Stefan Ewert

This inventor holds 15 USPTO granted patents and 5 published patent applications, plus 2 CIPO patents and 7 EPO patents. Top assignees: Esbatech, an Alcon Biomedical Research Unit LLC, Novartis Ag, Delenex Therapeutics Ag. Active years: 2011-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Stefan Ewert. Retrieved from https://idiyas.com/inventor/stefan-ewert

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 15 (Patent Applications = 5)

% Patents Active = 46.7

CIPO Patents = 2 (Patent Applications = 2)

EPO Patents = 7 (Patent Applications = 12)

Average Co-Inventor Count = 4.4

ph-index = 4

Forward Citations = 51(Granted Patents)

Location History:

Allschwill, CH (2012)
Allschwil, CH (2011 - 2016)
Basel, CH (2017)
Zurich, CH (2014 - 2020)
Geroldswill, DE (2019 - 2020)
Geroldswil, CH (2024)

Company Filing History:

7 out of 36

Esbatech, an Alcon Biomedical Research Unit LLC

Delenex Therapeutics Ag

Esbatech, an Alcon Boimedical Research Unit, LLC

patent

where one patent can have more than one assignee

Years Active: 2011-2025

Loading Chart...

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12331104 - Hepatitis B antibodies (2025-06-17),

2. 11932681 - Hepatitis B antibodies (2024-03-19),

3. 10647780 - Reversal binding agents for anti-factor XI/XIa antibodies and uses thereof (2020-05-12),

4. 10570190 - Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same (2020-02-25),

5. 10465011 - Factor XI antibodies and methods of use (2019-11-05),

6. 10125186 - Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same (2018-11-13),

7. 9683034 - Stable and soluble antibodies inhibiting TNFα (2017-06-20),

8. 9518108 - Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same (2016-12-13),

9. 9315572 - Stable and soluble antibodies inhibiting TNF alpha (2016-04-19),

10. 9273126 - Humanized antibodies against the beta-amyloid peptide (2016-03-01),

11. 8853362 - Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same (2014-10-07),

12. 8691228 - Stable and soluble antibodies inhibiting TNFα (2014-04-08),

13. 8389693 - Stable and soluble antibodies inhibiting TNFα (2013-03-05),

14. 8323647 - Humanized antibodies against the β-amyloid peptide (2012-12-04),

15. 8067547 - Stable and soluble antibodies inhibiting TNFα (2011-11-29),

Sure, here is the article about inventor Stefan Ewert:

Title: Inventor Spotlight: Stefan Ewert

Introduction:

Stefan Ewert, a talented inventor based in Allschwil, Switzerland, has made significant contributions to the field of biotechnology with a total of 13 patents to his name. His innovative work focuses on developing cutting-edge solutions in the realm of antibody research and intracellular stability.

Latest Patents:

1. "Reversal binding agents for anti-factor XI/XIa antibodies and uses thereof": Stefan Ewert's latest patent involves the creation of reversal agents that target anti-Factor XI and/or anti-Factor XIa antibodies. These agents effectively reverse the anticoagulant effects of the antibodies, offering new methods for managing bleeding risks.

2. "Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same": Another groundbreaking patent by Stefan Ewert revolves around the development of stable and soluble single-chain Fv antibody fragments. These frameworks are optimized for intracellular performance, making them ideal for applications requiring high stability and solubility.

Career Highlights:

Stefan Ewert has played a pivotal role in various companies, including Esbatech, an Alcon Biomedical Research Unit LLC, and Novartis Ag. His expertise and innovative approach have significantly influenced the biotechnology sector, leading to advancements in antibody research and intracellular stability.

Collaborations:

Throughout his career, Stefan Ewert has collaborated with notable professionals in the industry, including Adrian Auf Der Maur and Alcide Barberis. These collaborations have enhanced the scope of his inventions and paved the way for groundbreaking developments in biotechnology.

Conclusion:

In conclusion, Stefan Ewert stands as a remarkable inventor, with a remarkable portfolio of patents that have pushed the boundaries of biotechnology. His relentless pursuit of innovation and collaboration with industry experts reflect his dedication to advancing the field. Stefan Ewert's contributions continue to inspire and shape the future of antibody research and intracellular stability.

Profile summary based on public USPTO records.